Septerna Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing a GPCR-focused pipeline with SEP-479 in phase I for hypoparathyroidism, supported by strong financials and a Novo Nordisk partnership. Key programs target endocrine and metabolic diseases, with strategic plans for global commercialization and innovative trial designs.
-
The company is advancing an oral PTH receptor agonist for hypoparathyroidism, with full phase I data expected in Q1 next year, and is expanding its pipeline with programs in Graves' disease, osteoporosis, and mast cell diseases. Regulatory changes and platform innovations are enabling faster, more efficient development.
-
The meeting saw the election of two directors and ratification of the auditor, with all proposals approved. Key pipeline programs advanced, including SEP-479 and SEP-631, and strong financials were reported with $522 million in cash. Strategic partnerships and future clinical milestones were highlighted.
-
Two lead GPCR-targeting programs are advancing in clinical trials, with SEP-479 in phase I for hypoparathyroidism and SEP-631 moving to phase II for urticaria. The proprietary platform enables rapid discovery of novel drug candidates, and the pipeline includes additional programs for Graves' disease and incretin agonists.
-
SEP-631 showed robust phase I results and will enter a 12-week, dose-ranging phase II trial for chronic spontaneous urticaria in the second half of the year. SEP-479, an oral PTH agonist, is set to begin phase I trials soon, with titration and monitoring strategies to be refined in later phases.
-
SEP-631 demonstrated a favorable safety profile and robust, dose-dependent inhibition of MRGPRX2 signaling in a phase I trial, supporting once-daily oral dosing without food restrictions. These results validate clinical proof of mechanism and support advancement into phase II studies for chronic spontaneous urticaria and other mast cell-driven diseases.
-
The presentation highlighted rapid GPCR drug discovery enabled by the Native Complex Platform, with SEP-479 and SEP-631 advancing in clinical development for hypoparathyroidism and mast cell diseases, respectively. Strong market opportunities, robust IP, and strategic collaborations support a well-capitalized, diversified pipeline.
Fiscal Year 2025
-
The company presented progress on its GPCR-focused pipeline, highlighting SEP-479 for hyperparathyroidism and SEP-631 for mast cell diseases, both advancing toward key clinical milestones in 2024. A TSHR NAM program is also progressing, with Graves' disease as the initial target.
-
The summit highlighted progress on two lead programs: SEP-631, a once-daily oral MRGPRX2 inhibitor in phase I for mast cell diseases, and SEP-479, a PTH1 receptor agonist for hypoparathyroidism expected to enter the clinic next year. Additional pipeline and partnership updates were shared.
-
A novel GPCR drug discovery platform is advancing multiple programs, including SEP-479 for hyperparathyroidism and SEP-631 for mast cell diseases, both with strong preclinical and early clinical progress. A major Novo Nordisk collaboration and robust cash position support continued pipeline growth.
-
SEP-479, a next-generation PTH receptor agonist, showed strong preclinical efficacy and safety, with phase one trials planned for next year. SEP-631, targeting MRGPRX2, is in phase one with a broad indication strategy. A major Novo Nordisk partnership supports expansion into metabolic diseases.
-
The presentation highlighted a robust GPCR-focused drug discovery platform, major updates on SEP-479 for hypoparathyroidism with improved efficacy and safety, and progress on SEP-631 for mast cell diseases. Strong financials and strategic partnerships support a broad, advancing pipeline.
-
The presentation highlighted a robust GPCR-focused drug discovery platform, with multiple programs advancing in endocrinology, immunology, and metabolic disease. Next-generation candidates are progressing toward clinical trials, and a major Novo Nordisk collaboration strengthens financial runway and R&D capacity.
-
A proprietary platform enables rapid GPCR drug discovery, advancing four programs targeting major unmet needs. Lead asset SEP786, an oral PTH receptor agonist, is in phase 1 with mid-year data expected, while SEP631 and other programs progress toward the clinic.